New York, Jan 7, 2026, 11:50 a.m. EST — Regular session
- Structure Therapeutics shares rise about 6% in late-morning Nasdaq trade
- SEC filing details a $100 million upfront payment and low single-digit royalties tied to Roche/Genentech’s CT-996
- Focus turns to the full contract disclosure and the company’s next clinical and regulatory milestones
Shares of Structure Therapeutics Inc rose 5.6% to $66.75 in late-morning trade on Wednesday, recovering from early swings as investors sized up a newly disclosed patent license deal tied to Roche and Genentech’s oral obesity drug effort.
The agreement matters because it puts near-term cash on the table for a clinical-stage biotech and suggests its intellectual property has value beyond its own pipeline, at a moment when markets are quick to price any edge in the crowded GLP-1 weight-loss race.
A Form 8-K filing showed the company’s Gasherbrum Bio unit granted Genentech and Roche a non-exclusive, sublicensable license to certain patents covering a class of oral GLP-1 receptor agonists, allowing products containing Genentech’s CT-996 compound. Genentech agreed to pay $100 million within 30 days and royalties at a low single-digit rate — a small slice of future net sales — while the company said the license “does not encumber” its ongoing programs, including its lead GLP-1 candidate aleniglipron. The filing also described a covenant not to assert certain potential future patents, and said the full text of the agreement will be filed with the company’s annual report. SEC
BMO Capital reiterated an “Outperform” rating and a $130 price target after the filing, calling the arrangement “likely a mild positive” while arguing it was not the large pharma partnership some investors had been looking for. The firm said 2026 could still bring several catalysts, including an end-of-Phase 2 meeting with the U.S. FDA in the first half of the year. Investing.com
Roche, which has been building out its obesity pipeline, is paying up to reduce patent overhang around CT-996, according to industry coverage of the filing. CT-996 came to Roche via its Carmot Therapeutics buyout, and sits in a competitive field that includes Eli Lilly’s oral GLP-1 orforglipron and other attempts at pills that can match injections on weight loss and tolerability.
But the scope of the covered patents is still not spelled out in public detail, and the royalties are only worth something if CT-996 reaches the market. Traders also keep one eye on the usual biotech risk: trial or regulatory stumbles can erase a rally fast, especially in obesity drugs where side effects and dropouts can decide the narrative.
On the chart, Wednesday’s low near $63.26 marked the first obvious support, while the stock tested the $67 area on the upside as volume picked up from the open.
